NOVO B Stock Overview
Engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 4/6 |
| Financial Health | 4/6 |
| Dividends | 4/6 |
My Notes
Capture your thoughts, links and company narrative
Community Narratives
Create a narrativeNarratives bring a range of perspectives from our community.
Novo Nordisk A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 630.00 |
| 52 Week High | DKK 1,033.20 |
| 52 Week Low | DKK 526.00 |
| Beta | 0.20 |
| 1 Month Change | -19.49% |
| 3 Month Change | -23.22% |
| 1 Year Change | -13.58% |
| 3 Year Change | 93.67% |
| 5 Year Change | 207.17% |
| Change since IPO | 23,276.63% |
Recent News & Updates
Novo Nordisk A/S (CPH:NOVO B) Not Flying Under The Radar
Jan 09
Is Novo Nordisk (CPH:NOVO B) Using Too Much Debt?
Dec 23Recent updates
Novo Nordisk A/S (CPH:NOVO B) Not Flying Under The Radar
Jan 09Is Novo Nordisk (CPH:NOVO B) Using Too Much Debt?
Dec 23Solid Earnings May Not Tell The Whole Story For Novo Nordisk (CPH:NOVO B)
Nov 13Novo Nordisk A/S (CPH:NOVO B) Just Released Its Third-Quarter Earnings: Here's What Analysts Think
Nov 09Is Novo Nordisk A/S (CPH:NOVO B) Trading At A 31% Discount?
Nov 01Novo Nordisk A/S' (CPH:NOVO B) P/E Still Appears To Be Reasonable
Oct 09Is Novo Nordisk (CPH:NOVO B) Using Too Much Debt?
Jul 27Should You Be Adding Novo Nordisk (CPH:NOVO B) To Your Watchlist Today?
Jul 05A Look At The Fair Value Of Novo Nordisk A/S (CPH:NOVO B)
Jun 09Novo Nordisk's (CPH:NOVO B) Promising Earnings May Rest On Soft Foundations
May 09Results: Novo Nordisk A/S Beat Earnings Expectations And Analysts Now Have New Forecasts
May 04The Price Is Right For Novo Nordisk A/S (CPH:NOVO B)
Apr 28Does Novo Nordisk (CPH:NOVO B) Have A Healthy Balance Sheet?
Apr 14Do Novo Nordisk's (CPH:NOVO B) Earnings Warrant Your Attention?
Mar 18Shareholder Returns
| NOVO B | DK Pharmaceuticals | DK Market | |
|---|---|---|---|
| 7D | -1.4% | 2.1% | -1.6% |
| 1Y | -13.6% | -1.6% | -7.9% |
Return vs Industry: NOVO B underperformed the Danish Pharmaceuticals industry which returned -1.6% over the past year.
Return vs Market: NOVO B underperformed the Danish Market which returned -7.9% over the past year.
Price Volatility
| NOVO B volatility | |
|---|---|
| NOVO B Average Weekly Movement | 7.5% |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in DK Market | 11.5% |
| 10% least volatile stocks in DK Market | 2.8% |
Stable Share Price: NOVO B's share price has been volatile over the past 3 months compared to the Danish market.
Volatility Over Time: NOVO B's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of Danish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1923 | 71,880 | Lars Jorgensen | www.novonordisk.com |
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas.
Novo Nordisk A/S Fundamentals Summary
| NOVO B fundamental statistics | |
|---|---|
| Market cap | DKK 2.80t |
| Earnings (TTM) | DKK 94.72b |
| Revenue (TTM) | DKK 270.58b |
29.5x
P/E Ratio10.3x
P/S RatioIs NOVO B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NOVO B income statement (TTM) | |
|---|---|
| Revenue | DKK 270.58b |
| Cost of Revenue | DKK 41.51b |
| Gross Profit | DKK 229.07b |
| Other Expenses | DKK 134.35b |
| Earnings | DKK 94.72b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 05, 2025
| Earnings per share (EPS) | 21.33 |
| Gross Margin | 84.66% |
| Net Profit Margin | 35.01% |
| Debt/Equity Ratio | 47.3% |
How did NOVO B perform over the long term?
See historical performance and comparisonDividends
1.6%
Current Dividend Yield47%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/09 03:34 |
| End of Day Share Price | 2025/01/09 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Novo Nordisk A/S is covered by 70 analysts. 23 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | ABG Sundal Collier |
| Kamla Singh | AlphaValue |
| Gerhard Schwarz | Baader Helvea Equity Research |